Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Health systems and care delivery

Topic: Risk, prevention and care in population studies

Introduction: Given the elevated dementia risk in underrepresented demographic groups in the USA - particularly in Latino and Non-Latino Black individuals compared to Non-Latino White individuals - it is vital that these groups are well-represented in dementia prevention research. Eligibility criteria and recruitment strategies may play a key role in promoting participant diversity. The aim of this review was to examine eligibility criteria and recruitment strategies in US dementia prevention trials in light of participant diversity. A systematic review was conducted using Medline (including PubMed), Embase, Cochrane Library, and CINAHL. We explored the percent White participants for trials using versus not using a specific eligibility criterion or recruitment strategy using Hodges-Lehmann median difference estimation. Of forty-four studies meeting the inclusion criteria, twenty-seven reported on racial/ethnic diversity. Analyses demonstrated that criteria regarding cardiovascular disease, pulmonary disease, hearing impairment, and sedentary lifestyle were associated with relatively high participant diversity, while gastro-intestinal/liver disease, motivation to participate, and language proficiency criteria were associated with relatively little diversity. Information on recruitment strategies was often lacking. Three studies described recruitment efforts explicitly aimed at increasing diversity. Recruitment strategies associated with relatively high racial/ethnic diversity included recruitment via referral/word-of-mouth, television/radio advertising, and recruitment at church. Eligibility criteria could be improved by revisiting and revising how they are defined (e.g., motivation to participate). Regarding recruitment, several recommendations are provided, including (1) lifting barriers to study participation (e.g., through reimbursement), (2) collaborating with community partners, and (3) formally studying the effectiveness of recruitment strategies. .

Key findings

Why it matters

This review examined eligibility criteria and recruitment strategies in U.S. dementia prevention trials in relation to participant diversity. It does not test any treatment, cure, or prevention for Alzheimer's disease.

Study details

How this study scored 51/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 1 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 51 of 100.51 of 100 points earned49 not earned

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Dementia and geriatric cognitive disorders)
Journal's citation record 1 / 4 Dementia and Geriatric Cognitive Disorders: journal h-index 149 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 A review of other studies — randomisation is not credited here
Times cited 2 / 7 Cited 7 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.3 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 2.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Sanne Franzen: h-index 17 (OpenAlex, whole career)
Institution's track record 1 / 3 Erasmus MC: institution h-index 1,321 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 3 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39947158)
Free to read 0 / 2 Behind a paywall — scores zero
Total 51 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

APA 7th

Najoua, L., Van Beek Sabine, E., Rirash Awaale, F., Papma Janne, M., Jaime, P.-P., Shaw Ashley, R., et al. (2025). Diversity in United States Dementia Prevention Trials: An Updated Systematic Review of Eligibility Criteria and Recruitment Strategies. Dementia and geriatric cognitive disorders. https://doi.org/10.1159/000543905

Vancouver

Najoua L, Van Beek Sabine E, Rirash Awaale F, Papma Janne M, Jaime P.-P, Shaw Ashley R, et al. Diversity in United States Dementia Prevention Trials: An Updated Systematic Review of Eligibility Criteria and Recruitment Strategies. Dementia and geriatric cognitive disorders. 2025. doi:10.1159/000543905. PMID: 39947158.

BibTeX

@article{najoua2025-39947158,
  author  = {Najoua, Lazaar and Van Beek Sabine, E. and Rirash Awaale, F. and Papma Janne, M. and Jaime, Perales-Puchalt and Shaw Ashley, R. and Vidoni Eric, D. and Sanne, Franzen},
  title   = {{Diversity in United States Dementia Prevention Trials: An Updated Systematic Review of Eligibility Criteria and Recruitment Strategies}},
  journal = {Dementia and geriatric cognitive disorders},
  year    = {2025},
  doi     = {10.1159/000543905},
  pmid    = {39947158},
  url     = {https://doi.org/10.1159/000543905}
}

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Health systems and care delivery

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →